| Literature DB >> 29932137 |
Li-Guo Zheng1,2, Yu-Chia Chang3,4, Chiung-Chih Hu5, Zhi-Hong Wen6, Yang-Chang Wu7,8,9, Ping-Jyun Sung10,11,12,13,14.
Abstract
Two new briarane metabolites—fragilides K (1) and L (2)—along with five known analogues—gemmacolide X, praelolide, juncins P and ZI, and gemmacolide V (3⁻7)—were extracted and purified from Junceella fragilis, a gorgonian coral. Based on data obtained via spectroscopic techniques, the structures of new briaranes 1 and 2 were determined and the cyclohexane rings in 1 and 2 were found to exist in chair and twist boat conformation, respectively. Additionally, anti-inflammatory analysis showed that briaranes 2, 3, and 6 inhibited pro-inflammatory inducible nitric oxide synthase protein expression and briaranes 3 and 7 suppressed the cyclooxygenase-2 level, in LPS-stimulated murine macrophage-like RAW264.7 cells.Entities:
Keywords: COX-2; Junceella fragilis; briarane; fragilide; iNOS
Mesh:
Substances:
Year: 2018 PMID: 29932137 PMCID: PMC6100390 DOI: 10.3390/molecules23071510
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Gorgonian coral Junceella fragilis and structures of fragilides K (1) and L (2), gemmacolide X (3), praelolide (4), juncins P (5) and ZI (6), gemmacolide V (7), and junceellonoid B (8).
1H (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) NMR data, 1H–1H COSY, and HMBC correlations for briarane 1.
| C/H | δH ( | δC, Multiple | 1H–1H COSY | HMBC (H→C) |
|---|---|---|---|---|
| 1 | 46.9, C | |||
| 2 | 5.50 d (6.8) | 72.6, CH | H-3 | C-1, C-3, C-4, C-15, acetate carbonyl |
| 3 | 6.22 dd (10.8, 6.8) | 63.7, CH | H-2, H-4 | C-1, C-4, C-5, acetate carbonyl |
| 4 | 4.49 d (10.8) | 78.9, CH | H-3 | C-3, C-5, C-6, C-8, C-16 |
| 5 | 134.1, C | |||
| 6 | 4.96 d (2.8) | 53.8, CH | H-7 | n. o. |
| 7 | 4.42 d (2.8) | 79.0, CH | H-6 | C-5 |
| 8 | 83.0, C | |||
| 9 | 5.60 s | 71.1, CH | n. o. a | C-1, C-10, C-11, C-17, acetate carbonyl |
| 10 | 3.32 s | 35.1, CH | n. o. | C-1, C-8, C-11, C-12, C-15, C-20 |
| 11 | 58.9, C | |||
| 12 | 3.49 br s | 72.2, CH | H2-13 | n. o. |
| 13α/β | 2.20 ddd (15.6, 3.2, 2.8); 1.98 ddd (15.6, 3.2, 3.2) | 30.3, CH2 | H-12, H-14 | n. o. |
| 14 | 5.01 dd (3.2, 3.2) | 74.2, CH | H2-13 | n. o. |
| 15 | 1.24 s | 15.2, CH3 | C-1, C-2, C-10, C-14 | |
| 16a/b | 5.36 d (1.6); 5.57 d (1.6) | 119.7, CH2 | C-4, C-6 | |
| 17 | 2.79 q (7.2) | 49.6, CH | H3-18 | C-18, C-19 |
| 18 | 1.37 d (7.2) | 7.4, CH3 | H-17 | C-8, C-17, C-19 |
| 19 | 174.2, C | |||
| 20a/b | 2.76 d (3.2); 2.56 d (3.2) | 50.6, CH2 | n. o. | |
| OAc-2 | 170.2, C | |||
| 2.05 s | 20.5, CH3 | Acetate carbonyl | ||
| OAc-3 | 169.9, C | |||
| 2.08 s | 21.1, CH3 | Acetate carbonyl | ||
| OAc-9 | 169.5, C | |||
| 2.32 s | 21.1, CH3 | Acetate carbonyl | ||
| OAc-14 | 169.9, C | |||
| 2.00 s | 20.3, CH3 | Acetate carbonyl |
a n. o. = not observed.
Figure 2A model of 1 generated using a computer-assisted system based on the data from MM2 force field calculations and selected protons with key NOESY correlations.
1H (400 MHz, CDCl3) and 13C (100 MHz, CDCl3) NMR data, 1H–1H COSY and HMBC correlations for briarane 2
| C/H | δH ( | δC, Multiple | 1H–1HCOSY | HMBC (H→C) |
|---|---|---|---|---|
| 1 | 47.0, C | |||
| 2 | 4.83 dd (6.0, 1.2) | 75.9, CH | H2-3 | C-1, C-3, C-4, C-10, C-15, acetate carbonyl |
| 3α/β | 1.72 m; 2.49 m | 31.8, CH2 | H-2, H2-4 | C-1, C-4 |
| 4α/β | 2.26 m; 2.59 m | 26.2, CH2 | H2-3 | C-3, C-5, C-6, C-16 |
| 5 | 146.7, C | |||
| 6 | 5.94 d (10.0) | 121.7, CH | H-7 | C-4, C-16 |
| 7 | 5.30 d (10.0) | 77.3, CH | H-6 | C-5, C-6, C-8 |
| 8 | 83.2, C | |||
| 9 | 5.30 d (5.2) | 71.5, CH | H-10 | C-1, C-7, C-8, C-10, C-11, acetate carbonyl |
| 10 | 3.31 d (5.2) | 42.2, CH | H-9 | C-1, C-2, C-8, C-9, C-11, C-12, C-15, C-20 |
| 11 | 150.9, C | |||
| 12a/b | 2.26 m; 2.18 m | 26.4, CH2 | H2-13 | C-11, C-13, C-14, C-20 |
| 13a/b | 2.01 m; 1.76 m | 27.4, CH2 | H2-12, H-14 | C-1, C-11, C-14 |
| 14 | 4.72 dd (4.8, 1.6) | 73.8, CH | H2-13 | C-1, C-2, C-10, C-12, C-13, C-15, |
| acetate carbonyl | ||||
| 15 | 1.09 s | 15.1, CH3 | C-1, C-2, C-10, C-14 | |
| 16a/b | 4.28 dd (14.0, 5.2); 4.14 dd (14.0, 7.6) | 68.9, CH2 | OH-16 | C-5, C-6 |
| 17 | 2.47 q (7.2) | 42.6, CH | H3-18 | C-8, C-18, C-19 |
| 18 | 1.13 d (7.2) | 6.6, CH3 | H-17 | C-8, C-17, C-19 |
| 19 | 175.8, C | |||
| 20a/b | 4.90 s; 5.06 s | 113.1, CH2 | C-10, C-11, C-12 | |
| OAc-2 | 171.8, C | |||
| 2.01 s | 21.1, CH3 | Acetate carbonyl | ||
| OAc-9 | 169.4, C | |||
| 2.21 s | 21.8, CH3 | Acetate carbonyl | ||
| OAc-14 | 170.6, C | |||
| 1.91 s | 21.2, CH3 | Acetate carbonyl | ||
| OH-8 | 2.05 s | C-7, C-8, C-9, C-17 | ||
| OH-16 | 3.01 dd (7.6, 5.2) | H2-16 | n. o. a |
a n. o. = not observed.
Figure 3Selected protons with key NOESY correlations of 2.
Effects of 1–7 on iNOS and COX-2 protein expressions in LPS-stimulated macrophages.
| Compound | iNOS | COX-2 | β-Actin |
|---|---|---|---|
| Expression (% of LPS Group) | Expression (% of LPS Group) | Expression (% of LPS Group) | |
| Control | 1.01 ± 0.15 | 7.07 ± 3.88 | 86.12 ± 8.75 |
| LPS | 100 ± 11.26 | 100 ± 3.36 | 100 ± 0.07 |
|
| 61.22 ± 3.82 | 88.09 ± 6.87 | 94.26 ± 2.3 |
|
| 49.13 ± 4.15 | 80.08 ± 7.98 | 110.11 ± 3.16 |
|
| 36.22 ± 13.28 | 43.64 ± 6.23 | 99.30 ± 16.53 |
|
| 61.63 ± 21.36 | 81.55 ± 22.66 | 117.99 ± 6.04 |
|
| 76.16 ± 21.90 | 58.94 ± 0.8 | 117.48 ± 13.63 |
|
| 43.33 ± 10.82 | 68.87 ± 11.08 | 129.76 ± 25.75 |
|
| 74.65 ± 18.02 | 47.49 ± 1.49 | 124.60 ± 18.10 |
| Dex. a | 30.83 ± 6.69 | 9.32 ± 3.47 | 100.88 ± 3.14 |
a Dexamethasone (Dex., 10 μM) was used as a positive control.
Figure 4Effects of compounds 1–7 on the expression of pro-inflammatory iNOS and COX-2 proteins in lipopolysaccharide (LPS)-treated murine RAW264.7 macrophage cells. West blotting showed that briaranes 2, 3, and 6 inhibited LPS-induced iNOS expressions and briaranes 3 and 7 downregulated the expression of COX-2. Data were normalized to the cells treated with LPS only, and cells treated with dexamethasone (10 μM) were used as a positive control (which reduced the iNOS and COX-2 levels to 30.83 and 9.32%, respectively). Data are expressed as the mean ± SEM (n = 4). * Significantly different from cells treated with LPS (p < 0.05).